Qianlie Longbitong Tablets in Treating 45 Cases with Benign Prostatic Hyperplasia

NI Hong-hui; CHEN Hai-yan

doi:10.13422/j.cnki.syfjx.2015010182

您当前的位置：

首页 >

文章列表页 >

Qianlie Longbitong Tablets in Treating 45 Cases with Benign Prostatic Hyperplasia

更新时间：2024-01-04

- Qianlie Longbitong Tablets in Treating 45 Cases with Benign Prostatic Hyperplasia
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 1, Pages: 182-185(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015010182
  CLC： R277.5
- Published：2015
- 稿件说明：
移动端阅览
NI Hong-hui, CHEN Hai-yan. Qianlie Longbitong Tablets in Treating 45 Cases with Benign Prostatic Hyperplasia[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(1): 182-185.
DOI：

NI Hong-hui, CHEN Hai-yan. Qianlie Longbitong Tablets in Treating 45 Cases with Benign Prostatic Hyperplasia[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(1): 182-185. DOI： 10.13422/j.cnki.syfjx.2015010182.

摘要

目的: 观察前列癃闭通片保守治疗良性前列腺增生(BPH)的临床疗效及对血液流变学的影响。方法: 将90例BPH患者随机按数字表法分为西药组和中成药组各45例。西药组口服盐酸坦洛新缓释胶囊

0.2 mg/次

1次/晚;非那雄胺片

5 mg/次

1次/d

口服。中成药组服用前列癃闭通片

4片/次

3次/d。两组疗程均为12周。治疗前后进行国际前列腺症状评分(I-PSS)、肾(气)虚血瘀评分;B超检测前列腺大小、残余尿量(PVR)、最大尿流率(Qmax)、平均尿流率(Qave);治疗前后排尿症状对生活质量(QOL)评价;治疗前后血液流变学检测。结果: 经Ridit分析

中成药组疾病总体疗效和肾(气)虚血瘀证候疗效均优于西药组(P<0.05);治疗后中成药组I-PSS评分、QOL评分和肾(气)虚血瘀评分均低于西药组(P<0.01);治疗后两组前列腺体积较治疗前有所缩小(P<0.05或P<0.01);治疗后中成药组PVR少于西药组(P<0.01);中成药组Qmax

Qave均高于西药组(P<0.01);治疗后中成药组血液流变学指标全血黏度(低切、高切)、血浆黏度和全血还原黏度(低切、高切)低于西药组(P<0.01)。结论: 前列癃闭通片能缩小BPH(肾虚血瘀证)患者前列腺体积

减轻下尿道症状

提高患者生活质量

疾病总体疗效和中医证候疗效均显著。

Abstract

Objective: To observe the curative efficacy of conservative treatment of Qianlie Longbitong tablets on benign prostatic hyperplasia (BPH) and to discuss its influence on blood rheology. Method: Ninety patients were randomly divided into control group (45 cases) and observation group (45 cases) by random number table. Patients in control group received orally 0.2 mg tamsulosin hydrochloride sustained release capsules once every night and 5 mg finasteride tablets once daily. Patients in observation group received orally 4 Qianlie Longbitong tablets thrice daily. Patients in two groups received 12 weeks of treatment. International prostate symptom score (I-PSS)

kidney (gas) deficiency and blood stasis score were evaluated before and after treatment. Size of the prostate

residual urine volume (PVR)

maximum urinary flow rate (Qmax)

average urinary flow rate (Qave) were detected via type-B ultrasonic. The influence of urination on quality of life was evaluated. The blood rheology was tested before and after treatment. Result: Through Ridit analysis

the total efficacy of disease

kidney (gas) deficiency and blood stasis curative effect in observation group were superior to those in control group (P<0.05). After treatment

scores of I-PSS

QOL

kidney (gas) deficiency and blood stasis in observation group were less than those in control group (P<0.01). After treatment

prostate volume in two group was smaller as compared with that before (P<0.01 or P<0.05). PVR of observation group was lower than that of control group (P<0.01). Qmax and Qave of observation group were higher than those of control group (P<0.01). Besides

the improvement of blood rheology indexes as whole blood viscosity (low cut and high cut)

plasma viscosity and whole blood reductive viscosity (low cut and high cut) in observation group were superior to those in control group (P<0.01). Conclusion: Qianlie Longbitong tablets could shrink prostate volume with BPH (kidney deficiency and blood stasis) patients

relieve the symptoms of urinary tract and improve patient quality of life. It has certain effects on the total efficacy of disease and improvement in traditional Chinese medical syndrome.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring Mechanism of Kelong Capsules in Treatment of Benign Prostatic Hyperplasia Based on Nrf2 Pathway and Macrophage Activation

Cyclocarya paliurus Polysaccharide Inhibits Benign Prostatic Hyperplasia by Reducing 5α-Reductase 2

Clinical Efficacy of Fuzheng Huaji Longbi Decoction in Treating Benign Prostatic Hyperplasia with Syndrome of Healthy Qi Deficiency and Blood Stasis

Clinical Efficacy and Mechanism of Longdan Xiegantang in Treatment of Pelvic Inflammatory Infertility

Molecular Mechanism of Erzhiwan in Inhibiting Benign Prostatic Hyperplasia Base on Network Pharmacology

Related Author

SONG Guanhui

FAN Danping

LI Yan

LIU Hong

PAN Jinghua

WANG Shaojun

FAN Xiang

SUN Jian

Related Institution

Beijing University of Chinese Medicine

Experimental Research Center，China Academy of Chinese Medical Sciences

The First Clinical Medical College of Shaanxi University of Chinese Medicine

School of Pharmaceutical Sciences， Zhejiang Chinese Medical University

The First Affiliated Hospital of Henan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰